BBK Worldwide’s annual Research Voices surveys examine in with healthcare customers, medical professionals and pharmaceutical business leaders, providing a glimpse into their evolving ideas and perceptions on the scientific trial subject. Outsourcing-Pharma (OSP) lately spoke with Elizabeth Gargill, a member of BBK Worldwide’s market growth crew, about what the newest survey reveals and what the findings would possibly imply for scientific trial groups.
OSP: May you please share an outline of the Research Voices survey, i.e. its historical past, what the questions contact upon, who the respondents are, and what the surveys?
EG: The BBK Worldwide (BBK) Research Voices 2020 survey offers voice to the healthcare shopper and identifies shifts in attitudes and behaviors for the reason that onset of COVID-19 – perception that scientific trial sponsors can leverage for enrollment and engagement efforts. This survey is a part of our ongoing sequence of surveys designed to tell the affected person expertise – one thing BBK has been dedicated to for a few years as we work to assist sufferers extra simply combine scientific trial participation into their lives.
There’s no query that COVID-19 has been a catalyst for accelerating the adoption of a number of modern options as research shift to hybrid and digital fashions. Nonetheless, we wished to assemble knowledge that would inform long-term adoption and empower scientific trial sponsors to embrace options with confidence, so we centered on three areas:
- Telehealth adoption and long-term curiosity
- Instruments and applied sciences that affect scientific trial decision-making
- Shifts in scientific trial curiosity and consciousness
We divided the survey into three audiences: sufferers, medical professionals, and members of the pharmaceutical business for a complete of simply over 1,200 responses. We requested the medical professionals and members of the pharmaceutical business questions relative to their subject but in addition a few of the similar questions we requested the healthcare customers.
OSP: What are a few of the most notable affected person findings from this time round?
EG: The findings affirm a robust demand for telehealth. Sufferers cited comfort, decreased threat of COVID-19, and immediacy as vital components when requested what they like most about telehealth; comfort and immediacy are in keeping with what we already learn about right this moment’s healthcare shopper who calls for these of their healthcare expertise, so we’re not too stunned.
Nonetheless, we had been a bit stunned to see such a optimistic expertise with telehealth; 62%, of healthcare customers rated their expertise between 8 and 10 on a scale of 1 to 10 (1 = unfavourable; 10 = optimistic). Trying forward, 64% of healthcare customers wish to have a mixture of telehealth and in-person visits, whereas 26% favor in-person solely, and 10% favor telehealth solely.
The findings additionally reveal the options that matter most to sufferers when deciding on scientific trial participation. They ranked “speedy reimbursement” adopted by “entry to a examine web site,” and “having the ability to textual content message with examine employees” because the three most vital components.
Research apps, remedy supply, telehealth, and in-home nurse visits had been additionally vital. When it comes to boundaries to participation, out-of-pocket bills was on the high of the checklist.
As you would possibly anticipate from current information protection, we noticed dramatic progress in scientific trial consciousness, with 43% of healthcare customers indicating an elevated consciousness of scientific trials for the reason that onset of COVID-19 – with many citing expertise as a key issue that might make it simpler for them to take part.
OSP: What do you assume affected person respondents’ solutions about components like telehealth, boundaries to trial participation, motivations to enroll, and so forth., might be of use to trial websites and sponsors?
EG: I feel the solutions reinforce the significance of investing in instruments and applied sciences to help the affected person expertise, particularly as lives change into extra advanced within the wake of COVID-19. In addition they communicate to the truth that no matter a pandemic, a greater affected person expertise will be achieved with options that provide comfort, entry, and immediacy. So when examine visits will be performed remotely, they need to be, and when examine remedy will be delivered to a affected person’s residence, it needs to be, and so forth.
OSP: Equally, what are you able to inform us in regards to the responses given by the medical skilled respondents, and in regards to the pharma business respondents?
EG: We discovered fairly a bit from these audiences, and we might be releasing extra findings and evaluation quickly. But when we take a look at telehealth, for example, we noticed that the medical professionals and members of the pharmaceutical business had been aligned with sufferers by way of their want to include telehealth into healthcare administration shifting ahead. Sufferers and examine sponsors had been barely extra aligned of their total expertise and perspective in direction of telehealth.
It was additionally clear that telehealth creates efficiencies, with 53% of medical professionals indicating that telehealth visits allowed them to spend extra time with sufferers in comparison with in-person visits, and 69% indicating that telehealth visits helped them enhance their day by day affected person quantity.
OSP: COVID-19 looms massive everywhere in the scientific analysis and drug growth panorama—are you able to share how the pandemic’s affect exhibits up on this survey?
EG: The survey reveals that the pandemic has elevated willingness to contemplate scientific trial participation by 47%, which scientific trial sponsors can look to leverage. It exhibits that sufferers are comfy with expertise and keen to embracing telehealth with a view to decrease COVID-19 threat.
It additionally reveals that “concern about threat of publicity to COVID-19” is a high barrier to scientific trial participation proper now, which sponsors can handle with providers that improve affected person security corresponding to remedy supply, in-home nurse visits, and floor transportation that follows CDC private hygiene suggestions.
OSP: Is there the rest you’d like to inform us that we didn’t contact upon above?
EG: Between the three audiences we surveyed, there’s fairly a bit of information. We’ve solely launched our preliminary findings. We invite your readers to maintain an eye fixed out for the discharge of extra knowledge, out there on our web site, bbkworldwide.com.